Scribeable vs DeepScribe:
Scribeable delivers superior note quality at transparent, lower pricing. Built by clinicians with faster note generation and full web + mobile access with Apple Watch support.
Why Physicians Switch from DeepScribe
Slower note generation times frustrate physicians between patients
No free tier means you pay before you know if it works for your practice
Opaque pricing requires contacting sales for actual costs
Head-to-Head Comparison
Speed That Keeps Up With Your Day
Time between patients is measured in seconds, not minutes. DeepScribe's note generation can lag, forcing physicians to wait or move on and review later. Scribeable generates complete, specialty-specific notes in under 60 seconds — often before you've finished your hallway walk to the next exam room. That speed difference compounds across 20-30 patients per day.
Try Before You Buy
DeepScribe requires a sales conversation before you can evaluate the product. Scribeable lets you generate 15 notes for free every month — no credit card, no sales calls, no commitment. Experience the quality firsthand with your actual patients before making any financial decision. If it doesn't work for you, you've lost nothing.
Web + Mobile with Full Parity
DeepScribe offers a mobile app, but Scribeable gives you full web + mobile access under one subscription. Use the web dashboard at your desk, the iOS app in exam rooms, or start recordings from your Apple Watch — everything syncs seamlessly. Non-iOS users get the same full-featured experience through the web app. Use one, the other, or both — it's your workflow, your choice.
Same Patient. Same Encounter.
See why physicians say Scribeable notes are “actually usable” — with integrated risk scores, billing codes, and clinical reasoning that typical AI scribes simply don’t generate.
HPI
62 y/o male presents with chest pain for 2 hours. Substernal, pressure-like, radiating to left arm. Associated with diaphoresis and shortness of breath. Pain started while climbing stairs. Patient has history of HTN, DM2, and hyperlipidemia. Takes lisinopril, metformin, and atorvastatin. Denies recent illness or trauma.
Assessment & Plan
*Note examples are illustrative representations based on common AI documentation patterns. “Typical AI Scribe” represents composite characteristics of standard tools and does not depict any specific product. Patient scenarios are entirely fictional. Clinical notes should always be reviewed by a licensed provider.
AI Medical Scribe Note Quality Comparison
Scribeable produces clinically enriched notes with integrated risk calculators (HEART Score, CHA₂DS₂-VASc, Wells PE, PHQ-9, Caprini VTE), automated billing code optimization (E&M levels, HCC/RAF capture, CPT codes), dangerous diagnosis exclusion documentation, evidence-based prescribing citations, CMS compliance for operative reports, HEDIS care gap tracking, and MIPS quality measure documentation. Typical AI scribes produce basic notes without these advanced clinical features.
ED Chest Pain: 62-year-old male presenting with substernal chest pressure, diaphoresis, and exertional dyspnea
HPI: 62 y/o male presents with 2 hours of substernal chest pressure, rated 8/10, radiating to left arm and jaw. Onset during exertion (climbing stairs). Associated with diaphoresis and exertional dyspnea. Pressure-like quality, unrelieved by rest. No pleuritic component, no positional variation, no reproducibility with palpation. Risk factors: HTN (10 years), DM2 (8 years), hyperlipidemia, 30-pack-year smoking history (quit 5 years ago), family history of MI (father at age 58). Current medications: lisinopril 20mg daily, metformin 1000mg BID, atorvastatin 40mg daily. Denies cocaine use, recent immobilization, or prior VTE.
Assessment & Plan: 1. Acute Chest Pain — High-risk presentation HEART Score: 7 (High Risk) - History: moderately suspicious (2), EKG: non-specific ST changes (1), Age: >65 (2), Risk factors: ≥3 (2), Troponin: pending initial (0) - Risk stratification: >12% 6-week MACE event rate → full ACS workup - Serial troponins q3h, 12-lead EKG (initial + repeat at 60 min) - ASA 325mg PO administered, heparin drip per ACS protocol - Cardiology consulted for probable cath lab activation Dangerous Diagnosis Exclusion: - STEMI: No ST elevation on initial EKG — serial monitoring - Aortic dissection: No tearing quality, no pulse differential, no mediastinal widening on CXR - PE: Low pretest probability (Wells PE: 1.5) — no immobilization, no prior VTE, no hemoptysis 2. Hypertension — BP 168/94 on arrival, improved to 142/88 post-NTG - Continue home lisinopril, recheck prior to disposition 3. DM2 — Glucose 186 on arrival - Hold metformin (contrast exposure risk), sliding scale insulin PRN
Cardiology Consult: 71-year-old female with new-onset atrial fibrillation and decompensated heart failure
HPI: 71 y/o female with known HFrEF (EF 35% on TTE 6 months ago), HTN, DM2, and CKD Stage 3a (baseline Cr 1.4), consulted for new-onset atrial fibrillation with RVR. Progressive exertional dyspnea (NYHA II → IV over 2 weeks), 3-pillow orthopnea (new), PND, and 4+ pitting edema to knees bilaterally. Weight gain of 8 lbs over 2 weeks. Triggers explored: dietary indiscretion (holiday meals), medication non-adherence (ran out of furosemide 10 days ago). No prior AF history, no palpitations previously. Denies chest pain, syncope, or presyncope.
Assessment & Plan: Reason for Consult: New-onset atrial fibrillation with RVR in setting of acute decompensated HFrEF. Requesting Service: Internal Medicine (Dr. Patel) 1. New-onset Atrial Fibrillation with RVR CHA₂DS₂-VASc Score: 5 (Female sex, age ≥75, HTN, DM, HF) - Stroke risk: 6.7%/year → strong anticoagulation indication - Rate control: avoid diltiazem (negative inotropy in HFrEF) → amiodarone 150mg IV bolus then 1mg/min × 6h - Anticoagulation: apixaban 5mg BID (preferred over warfarin given age + fall risk) - TEE prior to any cardioversion attempt if AF duration uncertain - HAS-BLED: 2 (HTN, age) — acceptable bleeding risk 2. Acute Decompensated Heart Failure (ADHF) NYHA Functional Class: IV (dyspnea at rest) - IV furosemide 80mg BID (2.5× home oral dose), net negative 1-1.5L/day - Carvedilol held (acute decompensation), restart when euvolemic - Add sacubitril/valsartan when stable (PARADIGM-HF indication: EF ≤40% on ACEi) - BNP trend: 1,840 → monitor for response to diuresis 3. CKD Stage 3a — Cr 1.4 (baseline), monitor with aggressive diuresis - KDIGO risk: moderate — monitor Cr/K daily with diuresis
Operative Note: Right total knee arthroplasty in 68-year-old male with severe tricompartmental osteoarthritis
Operative Note: Preoperative Diagnosis: Right knee severe tricompartmental osteoarthritis (Kellgren-Lawrence Grade IV) Postoperative Diagnosis: Same Procedure: Right total knee arthroplasty Surgeon: Dr. James Morrison (attending — present and scrubbed for entire case) Assistant: Dr. Chen (PGY-4) Anesthesia: Spinal with sedation (Dr. Rivera) Implants: Smith & Nephew Legion CR, Size 5 femoral / Size 4 tibial / 10mm poly insert EBL: 150 mL Tourniquet Time: 62 minutes (pneumatic, 275 mmHg) Specimens: Femoral and tibial bone cuts — to pathology Complications: None Findings: Severe tricompartmental degenerative changes with exposed subchondral bone medially, grade III chondromalacia laterally, intact PCL
Post-Operative Plan: 1. Weight Bearing: WBAT right LE with front-wheeled walker 2. DVT Prophylaxis: Enoxaparin 40mg SQ daily × 14 days + mechanical (SCDs while inpatient) 3. Pain: Multimodal — scheduled acetaminophen 1g Q6h, meloxicam 15mg daily, tramadol 50mg Q6h PRN (max 14 days) 4. Antibiotics: Ancef 2g IV × 24h post-op 5. PT: Initiate POD0 PM — CPM machine, active/passive ROM, gait training 6. Follow-up: 2 weeks (staple removal + wound check), 6 weeks (X-ray + ROM assessment) 7. VTE Risk: Caprini Score 7 (High Risk) — extended pharmacologic prophylaxis indicated
Primary Care: 55-year-old female Medicare Advantage patient with DM2, HTN, depression, and overdue preventive care
HPI: 55 y/o female Medicare Advantage patient presenting for chronic disease management follow-up. Last visit 3 months ago. Diabetes (DM2, 8 years): A1c 8.2% (up from 7.6%), reports adherence but dietary indiscretion during holidays. Home glucose logs show fasting 140-180 range. No hypoglycemic episodes. Denies polyuria, polydipsia, vision changes, or foot numbness. Last diabetic eye exam: 14 months ago (overdue). Last podiatry visit: never. Hypertension (12 years): Home BP readings averaging 135-145/85-90. Taking lisinopril 20mg daily consistently. Depression (MDD, recurrent): PHQ-9 score today: 14 (moderately severe). Persistent low mood, anhedonia, poor sleep (initial insomnia), decreased concentration. On sertraline 50mg × 6 months with partial response. Denies SI/HI, denies alcohol or substance use. Columbia Suicide Severity: negative for ideation and behavior.
Assessment & Plan: 1. DM2, Uncontrolled (A1c 8.2%) — HCC 19 - Add empagliflozin 10mg daily (SGLT2i — CV and renal benefit, EMPA-REG OUTCOME indication) - Continue metformin 500mg BID (not escalating given GI intolerance history) - Diabetic eye exam referral (overdue 2 months — HEDIS measure) - Podiatry referral for initial foot exam - Recheck A1c in 3 months, target <7% 2. Hypertension, Suboptimally Controlled — HCC (when with CKD/DM) - BP today 138/86 — above target of <130/80 (ACC/AHA for DM patients) - Increase lisinopril to 40mg daily - Home BP log review in 4 weeks 3. Major Depressive Disorder, Recurrent, Moderate — HCC 59 - PHQ-9: 14 (moderately severe) — partial response to sertraline 50mg - Increase sertraline to 100mg daily - Safety plan reviewed, crisis line provided (988) - Follow-up in 4 weeks, recheck PHQ-9 - If inadequate response → consider augmentation or psychiatry referral 4. Preventive Care Gaps Addressed: - Mammogram ordered (last: 26 months ago — HEDIS BCS measure) - Colonoscopy referral (age 55, average risk, never screened — HEDIS COL) - Tobacco screening: former smoker, quit 3 years — MIPS measure 226 - Annual flu vaccine administered today — MIPS measure 110
Feature-by-Feature Comparison
Documentation
| Feature | Scribeable | DeepScribe |
|---|---|---|
| Ambient AI scribe | ||
| Multiple note types | ||
| Specialty templates | ||
| Note generation < 60sec | ||
| Multi-patient rounding modeRecord entire rounds, get all notes at once |
Platform
| Feature | Scribeable | DeepScribe |
|---|---|---|
| iOS native app | ||
| Apple Watch | ||
| Web app | ||
| Android app | ||
| EHR integration |
Billing
| Feature | Scribeable | DeepScribe |
|---|---|---|
| ICD-10 suggestions | ||
| E&M coding | ||
| HCC capture |
Pricing
| Feature | Scribeable | DeepScribe |
|---|---|---|
| Free tier | ||
| Published pricing | ||
| Month-to-month |
*Feature comparisons reflect publicly available information as of February 2026. Competitor capabilities may change. Revenue figures represent potential outcomes reported by select users and are not guaranteed. Individual results vary based on practice type, specialty, and patient volume.
Pricing Comparison
DeepScribe
Contact for pricing
Contact for pricing
Scribeable offers transparent pricing with superior note quality — no sales call required
Which Should You Choose?
Choose DeepScribe if you...
- Practices that need Android device support
- Organizations with specific DeepScribe EHR integrations
- Groups already under DeepScribe contract
Frequently Asked Questions
Compare Other Alternatives
vs Nuance DAX
Scribeable delivers superior note quality at 50-75% less cost. Built by clinicians who understand documentation pain points, with faster setup and no enterprise complexity.
vs Nabla
Scribeable offers superior note quality, more features, and better pricing — all built by clinicians who understand documentation needs. More note types, better billing, and lower cost.
vs Abridge
Scribeable delivers superior note quality built by clinicians, with more specialty support, comprehensive billing features, and transparent pricing accessible to all practitioners.
Try Scribeable Free — 15 Notes, No Credit Card
See why physicians switch from DeepScribe. Generate your first note in under 5 minutes.
Scribeable vs DeepScribe - AI Medical Scribe Comparison
Scribeable delivers superior note quality at transparent, lower pricing. Built by clinicians with faster note generation and full web + mobile access with Apple Watch support.
Why Physicians Switch from DeepScribe
- Slower note generation times frustrate physicians between patients
- No free tier means you pay before you know if it works for your practice
- Opaque pricing requires contacting sales for actual costs
Why Choose Scribeable Over DeepScribe
- Superior note quality — built by clinicians, for clinicians
- Simpler, transparent pricing ($89-149/month)
- Native iOS app with Apple Watch support
- Faster note generation (under 60 seconds)
- Free tier to try before buying
- No implementation required
- Unique Rounding Mode: record an entire round, get all notes at once — no competitor has this
Speed That Keeps Up With Your Day
Time between patients is measured in seconds, not minutes. DeepScribe's note generation can lag, forcing physicians to wait or move on and review later. Scribeable generates complete, specialty-specific notes in under 60 seconds — often before you've finished your hallway walk to the next exam room. That speed difference compounds across 20-30 patients per day.
Try Before You Buy
DeepScribe requires a sales conversation before you can evaluate the product. Scribeable lets you generate 15 notes for free every month — no credit card, no sales calls, no commitment. Experience the quality firsthand with your actual patients before making any financial decision. If it doesn't work for you, you've lost nothing.
Web + Mobile with Full Parity
DeepScribe offers a mobile app, but Scribeable gives you full web + mobile access under one subscription. Use the web dashboard at your desk, the iOS app in exam rooms, or start recordings from your Apple Watch — everything syncs seamlessly. Non-iOS users get the same full-featured experience through the web app. Use one, the other, or both — it's your workflow, your choice.
Feature Comparison: Scribeable vs DeepScribe
Documentation
| Feature | Scribeable | DeepScribe |
|---|---|---|
| Ambient AI scribe | Yes | Yes |
| Multiple note types | Yes | Yes |
| Specialty templates | Yes | Yes |
| Note generation < 60sec | Yes | Partial |
| Multi-patient rounding mode | Yes | No |
Platform
| Feature | Scribeable | DeepScribe |
|---|---|---|
| iOS native app | Yes | Yes |
| Apple Watch | Yes | No |
| Web app | Yes | Partial |
| Android app | No | Yes |
| EHR integration | Yes | Yes |
Billing
| Feature | Scribeable | DeepScribe |
|---|---|---|
| ICD-10 suggestions | Yes | Yes |
| E&M coding | Yes | Yes |
| HCC capture | Yes | Partial |
Pricing
| Feature | Scribeable | DeepScribe |
|---|---|---|
| Free tier | Yes | No |
| Published pricing | Yes | Partial |
| Month-to-month | Yes | Partial |
Pricing Comparison
Scribeable: Free, then $89-149/month
DeepScribe: Contact for pricing
Scribeable offers transparent pricing with superior note quality — no sales call required
What Physicians Say
DeepScribe notes took too long to generate and I was always waiting. Scribeable has my note ready before I walk into the next room. The Apple Watch recording is a bonus I didn't know I needed.
Dr. J. Thompson, Urgent Care, Multi-Site Practice
Which Should You Choose?
Choose Scribeable for superior note quality, transparent pricing, seamless web + mobile experience, and fastest note generation. Built by clinicians for clinicians. Choose DeepScribe only if you need Android support or their specific EHR integrations.
Frequently Asked Questions
Is Scribeable faster than DeepScribe for note generation?
Yes. Scribeable consistently generates complete notes in under 60 seconds, while DeepScribe's processing times can be longer. For high-volume practices seeing 20-30 patients per day, those extra minutes add up significantly.
Does Scribeable have Android support like DeepScribe?
Scribeable offers a full-featured web app accessible from any device, plus a native iOS app with Apple Watch support. Non-iOS users get the same documentation, billing, and workflow features through the web dashboard. If you specifically need a native Android app, DeepScribe may be a better fit.
How does Scribeable pricing compare to DeepScribe?
Scribeable publishes all pricing: free for 15 notes/month, $89/month for Pro, $149/month for Elite. DeepScribe requires contacting sales for pricing. Scribeable offers month-to-month plans with no contracts.
Can I try Scribeable for free before leaving DeepScribe?
Yes. Scribeable offers 15 free notes per month, no credit card required. Run both side by side to compare note quality, speed, and billing features before making a switch.
Explore More
Discover how Scribeable can help your practice with AI-powered clinical documentation